If you made any changes in Pure these will be visible here soon.

Research Output 1993 2018

Filter
Article
2018

A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors

NEPscore Working Group, Jun 1 2018, In : Endocrine-Related Cancer. 25, 6, p. 607-618 12 p.

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Survival
Italy
Calibration
Databases

A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors

NEPscore Working Group, Jun 2018, In : Endocrine-Related Cancer. 25, 6, p. 607-618 12 p.

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Survival
Italy
Calibration
Databases

A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors

Pusceddu, S., Barretta, F., Trama, A., Botta, L., Milione, M., Buzzoni, R., De Braud, F., Mazzaferro, V., Pastorino, U., Seregni, E., Mariani, L., Gatta, G., Di Bartolomeo, M., Femia, D., Prinzi, N., Coppa, J., Panzuto, F., Antonuzzo, L., Bajetta, E., Pia Brizzi, M. & 46 others, Campana, D., Catena, L., Comber, H., Dwane, F., Fazio, N., Faggiano, A., Giuffrida, D., Henau, K., Ibrahim, T., Marconcini, R., Massironi, S., Žakelj, M. P., Spada, F., Tafuto, S., Van Eycken, E., Van Der Zwan, J. M., Žagar, T., Giacomelli, L., Miceli, R., Francesca, A., Alberto, B., Rossana, B., Nicole, B., Sara, C., Carolina, C., Federica, C., Carlo, C., Francesca, C., Marilina, D., Vittoria, D. M., Chiara, D. D., Paola, E., Anna, L. S., Gabriele, L., Giuseppe, L. R., Federico, N., Alessandra, R., Vittorio, P., Paola, R., Maria, R., Sabine, S., Martina, T., Boukje, V. D., Otto, V., Claudio, V. & Group, NEP. W., 2018, In : Endocrine-Related Cancer. 25, 6, p. 607-618 12 p.

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Survival
Italy
Calibration
Databases
Esophagogastric Junction
Neoplasms
Ontario
Esophageal Neoplasms
General Practitioners

A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors

Peri, M., Botteri, E., Pisa, E., De Marinis, F., Ungaro, A., Spada, F., Grana, C. M., Gasparri, R., Spaggiari, L., Romentz, N., Badalamenti, G., Russo, A. & Fazio, N., Jul 2018, In : Journal of Thoracic Disease. 10, 7, p. 3928-3939 12 p.

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Neoplasm Metastasis
Lung
Recurrence
Bone and Bones

Assessment of response to treatment and follow-up in gastroenteropancreatic neuroendocrine neoplasms

Grimaldi, F., Fazio, N., Attanasio, R., Frasoldati, A., Papini, E., Cremonini, N., Davì, M. V., Funicelli, L., Massironi, S., Spada, F., Toscano, V., Versari, A., Zini, M., Falconi, M. & Öberg, K., Jan 1 2018, In : Endocrine, Metabolic and Immune Disorders - Drug Targets. 18, 5, p. 419-449 31 p.

Research output: Contribution to journalArticle

Neoplasms
Professional Competence
Medical Oncology
Patient Preference
Therapeutics

Assessment of response to treatment and follow-up in gastroenteropancreatic neuroendocrine neoplasms

Grimaldi, F., Fazio, N., Attanasio, R., Frasoldati, A., Papini, E., Cremonini, N., Davì, M. V., Funicelli, L., Massironi, S., Spada, F., Toscano, V., Versari, A., Zini, M., Falconi, M. & Öberg, K., 2018, In : Endocrine, Metabolic and Immune Disorders - Drug Targets. 18, 5, p. 419-449 31 p.

Research output: Contribution to journalArticle

Assessment of response to treatment and follow-up in gastroenteropancreatic neuroendocrine neoplasms

Grimaldi, F., Fazio, N., Attanasio, R., Frasoldati, A., Papini, E., Cremonini, N., Davì, M. V., Funicelli, L., Massironi, S., Spada, F., Toscano, V., Versari, A., Zini, M., Falconi, M. & Öberg, K., 2018, In : Endocrine, Metabolic and Immune Disorders - Drug Targets. 18, 5, p. 419-449 31 p.

Research output: Contribution to journalArticle

Neoplasms
Professional Competence
Medical Oncology
Patient Preference
Therapeutics

Efficacy and safety of sunitinib in patients with well-differentiated pancreatic neuroendocrine tumours

Raymond, E., Kulke, M. H., Qin, S., Yu, X., Schenker, M., Cubillo, A., Lou, W., Tomasek, J., Thiis-Evensen, E., Xu, J. M., Croitoru, A. E., Khasraw, M., Sedlackova, E., Borbath, I., Ruff, P., Oberstein, P. E., Ito, T., Jia, L., Hammel, P., Shen, L. & 10 others, Shrikhande, S. V., Shen, Y., Sufliarsky, J., Khan, G. N., Morizane, C., Galdy, S., Khosravan, R., Fernandez, K. C., Rosbrook, B. & Fazio, N., Nov 1 2018, In : Neuroendocrinology. 107, 3, p. 237-245 9 p.

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Safety
Disease-Free Survival
Confidence Intervals
Therapeutics

Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis

Fazio, N., Buzzoni, R., Delle Fave, G., Tesselaar, M. E., Wolin, E., Van Cutsem, E., Tomassetti, P., Strosberg, J., Voi, M., Bubuteishvili-Pacaud, L., Ridolfi, A., Herbst, F., Tomasek, J., Singh, S., Pavel, M., Kulke, M. H., Valle, J. W. & Yao, J. C., Jan 1 2018, In : Cancer Science. 109, 1, p. 174-181 8 p.

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Lung
Placebos
Disease-Free Survival
Confidence Intervals

Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis

Fazio, N., Buzzoni, R., Delle Fave, G., Tesselaar, M. E., Wolin, E., Van Cutsem, E., Tomassetti, P., Strosberg, J., Voi, M., Bubuteishvili-Pacaud, L., Ridolfi, A., Herbst, F., Tomasek, J., Singh, S., Pavel, M., Kulke, M. H., Valle, J. W. & Yao, J. C., 2018, In : Cancer Science. 109, 1, p. 174-181 8 p.

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Disease-Free Survival
Placebos
Confidence Intervals
Lung

Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary

Singh, S., Carnaghi, C., Buzzoni, R., Pommier, R. F., Raderer, M., Tomasek, J., Lahner, H., Valle, J. W., Voi, M., Bubuteishvili-Pacaud, L., Lincy, J., Wolin, E., Okita, N., Libutti, S. K., Oh, D-Y., Kulke, M., Strosberg, J., Yao, J. C., Pavel, M. E., Fazio, N. & 1 others, RAD001 in Advanced Neuroendocrine Tumors, F. T. RADIANT. S. G., 2018, In : Neuroendocrinology. 106, 3, p. 211-220 10 p.

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Gastrointestinal Tract
Disease-Free Survival
Placebos
Everolimus

Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary

RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial (RADIANT-4) Study Group, 2018, In : Neuroendocrinology. 106, 3, p. 211-220 10 p.

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Gastrointestinal Tract
Disease-Free Survival
Placebos
Everolimus

G3 GEP NENs category: are basic and clinical investigations well integrated?

Milione, M. & Fazio, N., Apr 1 2018, In : Endocrine. 60, 1, p. 28-30 3 p.

Research output: Contribution to journalArticle

Neoplasms
Carcinoma
Differential Diagnosis
Therapeutics
Clinical Trials

G3 GEP NENs category: are basic and clinical investigations well integrated?

Milione, M. & Fazio, N., 2018, In : Endocrine. 60, 1, p. 28-30 3 p.

Research output: Contribution to journalArticle

Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis

Milione, M., Maisonneuve, P., Pellegrinelli, A., Grillo, F., Albarello, L., Spaggiari, P., Vanoli, A., Tagliabue, G., Pisa, E., Messerini, L., Centonze, G., Inzani, F., Scarpa, A., Papotti, M., Volante, M., Sessa, F., Fazio, N., Pruneri, G., Rindi, G., Solcia, E. & 2 others, Rosa, S. L. & Capella, C., May 1 2018, In : Endocrine-Related Cancer. 25, 5, p. 583-593 11 p.

Research output: Contribution to journalArticle

Carcinoma
Neuroendocrine Carcinoma
Digestive System
DNA Mismatch Repair
Survival

Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis

Milione, M., Maisonneuve, P., Pellegrinelli, A., Grillo, F., Albarello, L., Spaggiari, P., Vanoli, A., Tagliabue, G., Pisa, E., Messerini, L., Centonze, G., Inzani, F., Scarpa, A., Papotti, M., Volante, M., Sessa, F., Fazio, N., Pruneri, G., Rindi, G., Solcia, E. & 2 others, Rosa, S. L. & Capella, C., 2018, In : Endocrine-Related Cancer. 25, 5, p. 583-593 11 p.

Research output: Contribution to journalArticle

Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis

Milione, M., Maisonneuve, P., Pellegrinelli, A., Grillo, F., Albarello, L., Spaggiari, P., Vanoli, A., Tagliabue, G., Pisa, E., Messerini, L., Centonze, G., Inzani, F., Scarpa, A., Papotti, M., Volante, M., Sessa, F., Fazio, N., Pruneri, G., Rindi, G., Solcia, E. & 2 others, Rosa, S. L. & Capella, C., 2018, In : Endocrine-Related Cancer. 25, 5, p. 583-593 11 p.

Research output: Contribution to journalArticle

Carcinoma
Neuroendocrine Carcinoma
Digestive System
DNA Mismatch Repair
Survival

Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis

Milione, M., Maisonneuve, P., Pellegrinelli, A., Grillo, F., Albarello, L., Spaggiari, P., Vanoli, A., Tagliabue, G., Pisa, E., Messerini, L., Centonze, G., Inzani, F., Scarpa, A., Papotti, M., Volante, M., Sessa, F., Fazio, N., Pruneri, G., Rindi, G., Solcia, E. & 2 others, Rosa, S. L. & Capella, C., May 1 2018, In : Endocrine-Related Cancer. 25, 5, p. 583-593 11 p.

Research output: Contribution to journalArticle

Carcinoma
Neuroendocrine Carcinoma
Survival
Digestive System
Confidence Intervals

Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis

Milione, M., Maisonneuve, P., Pellegrinelli, A., Grillo, F., Albarello, L., Spaggiari, P., Vanoli, A., Tagliabue, G., Pisa, E., Messerini, L., Centonze, G., Inzani, F., Scarpa, A., Papotti, M., Volante, M., Sessa, F., Fazio, N., Pruneri, G., Rindi, G., Solcia, E. & 2 others, La Rosa, S. & Capella, C., May 2018, In : Endocrine-Related Cancer. 25, 5, p. 583-593 11 p.

Research output: Contribution to journalArticle

Carcinoma
Neuroendocrine Carcinoma
Survival
Digestive System
Confidence Intervals

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues

Pusceddu, S., Vernieri, C., Di Maio, M., Marconcini, R., Spada, F., Massironi, S., Ibrahim, T., Brizzi, M. P., Campana, D., Faggiano, A., Giuffrida, D., Rinzivillo, M., Cingarlini, S., Aroldi, F., Antonuzzo, L., Berardi, R., Catena, L., De Divitiis, C., Ermacora, P., Perfetti, V. & 32 others, Fontana, A., Razzore, P., Carnaghi, C., Davì, M. V., Cauchi, C., Duro, M., Ricci, S., Fazio, N., Cavalcoli, F., Bongiovanni, A., La Salvia, A., Brighi, N., Colao, A., Puliafito, I., Panzuto, F., Ortolani, S., Zaniboni, A., Di Costanzo, F., Torniai, M., Bajetta, E., Tafuto, S., Garattini, S. K., Femia, D., Prinzi, N., Concas, L., Lo Russo, G., Milione, M., Giacomelli, L., Buzzoni, R., Delle Fave, G., Mazzaferro, V. & de Braud, F., Aug 2018, In : Gastroenterology. 155, 2, p. 479-489.e7

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Metformin
Somatostatin
Disease-Free Survival
Everolimus

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues

Pusceddu, S., Vernieri, C., Di Maio, M., Marconcini, R., Spada, F., Massironi, S., Ibrahim, T., Brizzi, M. P., Campana, D., Faggiano, A., Giuffrida, D., Rinzivillo, M., Cingarlini, S., Aroldi, F., Antonuzzo, L., Berardi, R., Catena, L., De Divitiis, C., Ermacora, P., Perfetti, V. & 30 others, Fontana, A., Razzore, P., Carnaghi, C., Davì, M. V., Cauchi, C., Duro, M., Ricci, S., Fazio, N., Cavalcoli, F., Bongiovanni, A., La Salvia, A., Brighi, N., Colao, A., Puliafito, I., Panzuto, F., Ortolani, S., Zaniboni, A., Di Costanzo, F., Torniai, M., Bajetta, E., Tafuto, S., Garattini, S. K., Femia, D., Prinzi, N., Concas, L., Lo Russo, G., Milione, M., Buzzoni, R., Mazzaferro, V. & de Braud, F., Aug 1 2018, In : Gastroenterology. 155, 2, p. 479-489.e7

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Metformin
Somatostatin
Disease-Free Survival
Everolimus

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues

Pusceddu, S., Vernieri, C., Di Maio, M., Marconcini, R., Spada, F., Massironi, S., Ibrahim, T., Brizzi, M. P., Campana, D., Faggiano, A., Giuffrida, D., Rinzivillo, M., Cingarlini, S., Aroldi, F., Antonuzzo, L., Berardi, R., Catena, L., De Divitiis, C., Ermacora, P., Perfetti, V. & 32 others, Fontana, A., Razzore, P., Carnaghi, C., Davì, M. V., Cauchi, C., Duro, M., Ricci, S., Fazio, N., Cavalcoli, F., Bongiovanni, A., La Salvia, A., Brighi, N., Colao, A., Puliafito, I., Panzuto, F., Ortolani, S., Zaniboni, A., Di Costanzo, F., Torniai, M., Bajetta, E., Tafuto, S., Garattini, S. K., Femia, D., Prinzi, N., Concas, L., Lo Russo, G., Milione, M., Giacomelli, L., Buzzoni, R., Delle Fave, G., Mazzaferro, V. & de Braud, F., 2018, In : Gastroenterology. 155, 2, p. 479-489.e7

Research output: Contribution to journalArticle

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues

Pusceddu, S., Vernieri, C., Di Maio, M., Marconcini, R., Spada, F., Massironi, S., Ibrahim, T., Brizzi, M. P., Campana, D., Faggiano, A., Giuffrida, D., Rinzivillo, M., Cingarlini, S., Aroldi, F., Antonuzzo, L., Berardi, R., Catena, L., De Divitiis, C., Ermacora, P., Perfetti, V. & 32 others, Fontana, A., Razzore, P., Carnaghi, C., Davì, M. V., Cauchi, C., Duro, M., Ricci, S., Fazio, N., Cavalcoli, F., Bongiovanni, A., La Salvia, A., Brighi, N., Colao, A., Puliafito, I., Panzuto, F., Ortolani, S., Zaniboni, A., Di Costanzo, F., Torniai, M., Bajetta, E., Tafuto, S., Garattini, S. K., Femia, D., Prinzi, N., Concas, L., Lo Russo, G., Milione, M., Giacomelli, L., Buzzoni, R., Delle Fave, G., Mazzaferro, V. & de Braud, F., 2018, In : Gastroenterology. 155, 2, p. 479

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Metformin
Somatostatin
Disease-Free Survival
Everolimus

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues

Pusceddu, S., Vernieri, C., Di Maio, M., Marconcini, R., Spada, F., Massironi, S., Ibrahim, T., Brizzi, M. P., Campana, D., Faggiano, A., Giuffrida, D., Rinzivillo, M., Cingarlini, S., Aroldi, F., Antonuzzo, L., Berardi, R., Catena, L., De Divitiis, C., Ermacora, P., Perfetti, V. & 32 others, Fontana, A., Razzore, P., Carnaghi, C., Davì, M. V., Cauchi, C., Duro, M., Ricci, S., Fazio, N., Cavalcoli, F., Bongiovanni, A., La Salvia, A., Brighi, N., Colao, A., Puliafito, I., Panzuto, F., Ortolani, S., Zaniboni, A., Di Costanzo, F., Torniai, M., Bajetta, E., Tafuto, S., Garattini, S. K., Femia, D., Prinzi, N., Concas, L., Lo Russo, G., Milione, M., Giacomelli, L., Buzzoni, R., Delle Fave, G., Mazzaferro, V. & de Braud, F., Aug 2018, In : Gastroenterology. 155, 2, p. 479-489.e7

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Metformin
Somatostatin
Disease-Free Survival
Everolimus

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues

Pusceddu, S., Vernieri, C., Di Maio, M., Marconcini, R., Spada, F., Massironi, S., Ibrahim, T., Brizzi, M. P., Campana, D., Faggiano, A., Giuffrida, D., Rinzivillo, M., Cingarlini, S., Aroldi, F., Antonuzzo, L., Berardi, R., Catena, L., De Divitiis, C., Ermacora, P., Perfetti, V. & 32 others, Fontana, A., Razzore, P., Carnaghi, C., Davì, M. V., Cauchi, C., Duro, M., Ricci, S., Fazio, N., Cavalcoli, F., Bongiovanni, A., La Salvia, A., Brighi, N., Colao, A., Puliafito, I., Panzuto, F., Ortolani, S., Zaniboni, A., Di Costanzo, F., Torniai, M., Bajetta, E., Tafuto, S., Garattini, S. K., Femia, D., Prinzi, N., Concas, L., Lo Russo, G., Milione, M., Giacomelli, L., Buzzoni, R., Delle Fave, G., Mazzaferro, V. & de Braud, F., 2018, In : Gastroenterology. 155, 2, p. 479

Research output: Contribution to journalArticle

Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms

Partelli, S., Bertani, E., Bartolomei, M., Perali, C., Muffatti, F., Grana, C. M., Schiavo Lena, M., Doglioni, C., Crippa, S., Fazio, N., Zamboni, G. & Falconi, M., Apr 1 2018, In : Surgery (United States). 163, 4, p. 761-767 7 p.

Research output: Contribution to journalArticle

Neoadjuvant Therapy
Peptide Receptors
Pancreatic Neoplasms
Radioisotopes
Group Psychotherapy

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study

Rinzivillo, M., Fazio, N., Pusceddu, S., Spallanzani, A., Ibrahim, T., Campana, D., Marconicini, R., Partelli, S., Badalamenti, G., Brizzi, M. P., Catena, L., Schinzari, G., Carnaghi, C., Berardi, R., Faggiano, A., Antonuzzo, L., Spada, F., Gritti, S., Femia, D., Gelsomino, F. & 6 others, Bongiovanni, A., Ricci, S., Brighi, N., Falconi, M., Delle Fave, G. & Panzuto, F., Mar 2018, In : Pancreatology. 18, 2, p. 198-203 6 p.

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Therapeutics
Disease-Free Survival
sunitinib
Neoplasms

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study

Rinzivillo, M., Fazio, N., Pusceddu, S., Spallanzani, A., Ibrahim, T., Campana, D., Marconicini, R., Partelli, S., Badalamenti, G., Brizzi, M. P., Catena, L., Schinzari, G., Carnaghi, C., Berardi, R., Faggiano, A., Antonuzzo, L., Spada, F., Gritti, S., Femia, D., Gelsomino, F. & 6 others, Bongiovanni, A., Ricci, S., Brighi, N., Falconi, M., Delle Fave, G. & Panzuto, F., Jan 1 2018, In : Pancreatology.

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Therapeutics
sunitinib
Disease-Free Survival
Neoplasms

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study

Rinzivillo, M., Fazio, N., Pusceddu, S., Spallanzani, A., Ibrahim, T., Campana, D., Marconicini, R., Partelli, S., Badalamenti, G., Brizzi, M. P., Catena, L., Schinzari, G., Carnaghi, C., Berardi, R., Faggiano, A., Antonuzzo, L., Spada, F., Gritti, S., Femia, D., Gelsomino, F. & 6 others, Bongiovanni, A., Ricci, S., Brighi, N., Falconi, M., Delle Fave, G. & Panzuto, F., 2018, In : Pancreatology. 18, 2, p. 198-203 6 p.

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Therapeutics
sunitinib
Disease-Free Survival
Neoplasms
2017

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

Kulke, M. H., Ruszniewski, P., Van Cutsem, E., Lombard-Bohas, C., Valle, J. W., De Herder, W. W., Pavel, M., Degtyarev, E., Brase, J. C., Bubuteishvili-Pacaud, L., Voi, M., Salazar, R., Borbath, I., Fazio, N., Smith, D., Capdevila, J., Riechelmann, R. P. & Yao, J. C., Jun 1 2017, In : Annals of Oncology. 28, 6, p. 1309-1315 7 p., mdx078.

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Disease-Free Survival
Somatostatin
Safety
Chromogranin A

Dual modulation of MCL-1 and mTOR determines the response to sunitinib

Elgendy, M., Abdel-Aziz, A. K., Renne, S. L., Bornaghi, V., Procopio, G., Colecchia, M., Kanesvaran, R., Toh, C. K., Bossi, D., Pallavicini, I., Perez-Gracia, J. L., Lozano, M. D., Giandomenico, V., Mercurio, C., Lanfrancone, L., Fazio, N., Nole, F., Teh, B. T., Renne, G. & Minucci, S., 2017, In : Journal of Clinical Investigation. 127, 1, p. 153-168 16 p.

Research output: Contribution to journalArticle

Dual modulation of MCL-1 and mTOR determines the response to sunitinib

Elgendy, M., Abdel-Aziz, A. K., Renne, S. L., Bornaghi, V., Procopio, G., Colecchia, M., Kanesvaran, R., Toh, C. K., Bossi, D., Pallavicini, I., Perez-Gracia, J. L., Lozano, M. D., Giandomenico, V., Mercurio, C., Lanfrancone, L., Fazio, N., Nole, F., Teh, B. T., Renne, G. & Minucci, S., Jan 3 2017, In : Journal of Clinical Investigation. 127, 1, p. 153-168 16 p.

Research output: Contribution to journalArticle

sunitinib
Protein Stability
Protein-Tyrosine Kinases
Neoplasms
mechanistic target of rapamycin complex 1

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Biotherapy and Novel Targeted Agents

Pavel, M., Valle, J. W., Eriksson, B., Rinke, A., Caplin, M., Chen, J., Costa, F., Falkerby, J., Fazio, N., Gorbounova, V., De Herder, W., Kulke, M., Lombard-Bohas, C., O'Connor, J., Sorbye, H. & Garcia-Carbonero, R., Sep 1 2017, In : Neuroendocrinology. 105, 3, p. 266-280 15 p.

Research output: Contribution to journalArticle

Biological Therapy
Standard of Care
Neuroendocrine Tumors
Guidelines
Pharmaceutical Preparations

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Chemotherapy

Garcia-Carbonero, R., Rinke, A., Valle, J. W., Fazio, N., Caplin, M., Gorbounova, V., O'Connor, J., Eriksson, B., Sorbye, H., Kulke, M., Chen, J., Falkerby, J., Costa, F., De Herder, W., Lombard-Bohas, C. & Pavel, M., Sep 1 2017, In : Neuroendocrinology. 105, 3, p. 281-294 14 p.

Research output: Contribution to journalArticle

Standard of Care
Guidelines
Drug Therapy
irinotecan
Neuroendocrine Tumors

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging

Sundin, A., Arnold, R., Baudin, E., Cwikla, J. B., Eriksson, B., Fanti, S., Fazio, N., Giammarile, F., Hicks, R. J., Kjaer, A., Krenning, E., Kwekkeboom, D., Lombard-Bohas, C., O'Connor, J. M., O'Toole, D., Rockall, A., Wiedenmann, B., Valle, J. W. & Vullierme, M. P., Sep 1 2017, In : Neuroendocrinology. 105, 3, p. 212-244 33 p.

Research output: Contribution to journalArticle

Multimodal Imaging
Neuroendocrine Tumors
Nuclear Medicine
Standard of Care
Tomography

Everolimus in pancreatic neuroendocrine carcinomas G3

Panzuto, F., Rinzivillo, M., Spada, F., Antonuzzo, L., Ibrahim, T., Campana, D., Fazio, N. & Delle Fave, G., 2017, In : Pancreas. 46, 3, p. 302-305 4 p.

Research output: Contribution to journalArticle

Everolimus in pancreatic neuroendocrine carcinomas G3

Panzuto, F., Rinzivillo, M., Spada, F., Antonuzzo, L., Ibrahim, T., Campana, D., Fazio, N. & Delle Fave, G., Mar 1 2017, In : Pancreas. 46, 3, p. 302-305 4 p.

Research output: Contribution to journalArticle

Neuroendocrine Carcinoma
Disease-Free Survival
Drug Therapy
Peptide Receptors
Poisons

Everolimus-related adverse events in neuroendocrine tumors and comparative considerations with breast and renal cancer: a critical overview

Martins, D., Lambrescu, I., Barucca, V. & Fazio, N., Jun 3 2017, In : Expert Opinion on Orphan Drugs. 5, 6, p. 525-536 12 p.

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Kidney Neoplasms
Breast Neoplasms
Sirolimus
Therapeutics

Gastroenteropancreatic neuroendocrine carcinomas: The NET G3 subcategory is a reality

Fazio, N. & Milione, M., 2017, In : Oncologist. 22, 3, p. 359-360 2 p.

Research output: Contribution to journalArticle

Grading lung neuroendocrine tumors: Controversies in search of a solution

Pelosi, G., Pattini, L., Morana, G., Fabbri, A., Faccinetto, A., Fazio, N., Valeri, B. & Sonzogni, A., 2017, In : Histology and Histopathology. 32, 3, p. 223-241 19 p.

Research output: Contribution to journalArticle

Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Pavel, M. E., Singh, S., Strosberg, J. R., Bubuteishvili-Pacaud, L., Degtyarev, E., Neary, M. P., Carnaghi, C., Tomasek, J., Wolin, E., Raderer, M., Lahner, H., Valle, J. W., Pommier, R., Van Cutsem, E., Tesselaar, M. E. T., Fave, G. D., Buzzoni, R., Hunger, M., Eriksson, J., Cella, D. & 4 others, Ricci, J. F., Fazio, N., Kulke, M. H. & Yao, J. C., Oct 1 2017, In : The Lancet Oncology. 18, 10, p. 1411-1422 12 p.

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Placebos
Quality of Life
Lung
Disease-Free Survival

Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Pavel, M. E., Singh, S., Strosberg, J. R., Bubuteishvili-Pacaud, L., Degtyarev, E., Neary, M. P., Carnaghi, C., Tomasek, J., Wolin, E., Raderer, M., Lahner, H., Valle, J. W., Pommier, R., Van Cutsem, E., Tesselaar, M. E. T., Fave, G. D., Buzzoni, R., Hunger, M., Eriksson, J., Cella, D. & 4 others, Ricci, J-F., Fazio, N., Kulke, M. H. & Yao, J. C., 2017, In : The Lancet Oncology. 18, 10, p. 1411-1422 12 p.

Research output: Contribution to journalArticle

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

Galdy, S., Lamarca, A., McNamara, M. G., Hubner, R. A., Cella, C. A., Fazio, N. & Valle, J. W., Mar 1 2017, In : Cancer and Metastasis Reviews. 36, 1, p. 141-157 17 p.

Research output: Contribution to journalArticle

Biliary Tract
Epidermal Growth Factor Receptor
Meta-Analysis
Biliary Tract Neoplasms
Neoplasms

Impact of prior therapies on everolimus activity: An exploratory analysis of RADIANT-4

Buzzoni, R., Carnaghi, C., Strosberg, J., Fazio, N., Singh, S., Herbst, F., Ridolfi, A., Pavel, M. E., Wolin, E. M., Valle, J. W., Oh, D. Y., Yao, J. C. & Pommier, R., Oct 16 2017, In : OncoTargets and Therapy. 10, p. 5013-5030 18 p.

Research output: Contribution to journalArticle

Peptide Receptors
Somatostatin
Radioisotopes
Drug Therapy
Neuroendocrine Tumors

Impact of prior therapies on everolimus activity: An exploratory analysis of RADIANT-4

Buzzoni, R., Carnaghi, C., Strosberg, J., Fazio, N., Singh, S., Herbst, F., Ridolfi, A., Pavel, M. E., Wolin, E. M., Valle, J. W., Oh, D-Y., Yao, J. C. & Pommier, R., 2017, In : OncoTargets and Therapy. 10, p. 5013-5030 18 p.

Research output: Contribution to journalArticle

Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors

Martins, D., Spada, F., Lambrescu, I., Rubino, M., Cella, C., Gibelli, B., Grana, C., Ribero, D., Bertani, E., Ravizza, D., Bonomo, G., Funicelli, L., Pisa, E., Zerini, D., Fazio, N. & IEO ENETS Center of Excellence for GEP NETs, Oct 1 2017, In : Targeted Oncology. 12, 5, p. 611-622 12 p.

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Neoplasms
Sirolimus
Therapeutics
Tumor Biomarkers

Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: A multicenter study

Davi, M. V., Cosaro, E., Piacentini, S., Reimondo, G., Albiger, N., Arnaldi, G., Faggiano, A., Mantovani, G., Fazio, N., Piovesan, A., Arvat, E., Grimaldi, F., Canu, L., Mannelli, M., Ambrogio, A. G., Giraldi, F. P., Martini, C., Lania, A., Albertelli, M., Ferone, D. & 9 others, Zatelli, M. C., Campana, D., Colao, A., Scaroni, C., Terzolo, M., Marinis, L. D., Cingarlini, S., Micciolo, R. & Francia, G., Apr 1 2017, In : European Journal of Endocrinology. 176, 4, p. 453-461 9 p.

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Cushing Syndrome
Multicenter Studies
Carcinoid Tumor
Survival